The Medicines Patent Pool (MPP) was honoured to present its Strategy 2023-2025 on Monday 30 January 2023. Since 2010, MPP has signed 34 licences for different health technologies and facilitated access to over 30 billion doses of treatments. Over the next three years, MPP will aim to conclude licences for ten innovative health products and support the introduction of affordable versions of five products that will help to improve the standard of care in LMICs across the different diseases in which MPP works. We will also support technology transfer of mRNA vaccine technology to ten manufacturers. We expect that our licences will allow 30 million people to benefit annually, double from where it stands today and contribute to saving USD 1.2 billion.
Welcome and introduction
Panel discussion 1 – Goal 1: Expand access to innovative medicines for infectious diseases Goal 2: Establish voluntary licensing as an impactful access mechanism for other diseases and conditions
Panel discussion 2 – Goal 3: Facilitate development and access to novel medical technologies Goal 4: Accelerate equitable access to countermeasures for pandemics and other international health emergencies Goal 5: Support diversified and sustainable manufacturing capacity
Closing remarks
Watch our panel discussions and strategy launch that took place on 30 January 2023 in Geneva. (1h 6 mins)
Watch Greg Martin explain our new strategy that centres around five core goals for greater access to vital medicines and health technologies in lower- and middle-income countries. The Strategy also explains how these goals will be achieved, as well as outlining key MPP achievements since its inception in 2010. (4 mins)
Dr Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, spoke about the need for a greater global response to reversing inequitable access to vital health medicines and technologies in lower- and middle-income countries. He stressed that MPP’s new Strategy offered a way forward to overcome these inequities. (2 mins)
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.